


## JQAD1

## Chemical Properties

CAS No. :	2417097-18-6
Formula:	C48H52F4N6O9
Molecular Weight:	932.95
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	JQAD1 is a potent and selective histone acetyltransferase EP300 degrader (PROTAC®; DC50 ≤ 31.6 nM); comprises an EP300 inhibitor, A485, joined by a linker to a cereblon E3 ligase ligand. JQAD1 brings about degradation of EP300 in neuroblastoma cell lines in a proteasome-dependent manner. JQAD1 suppresses both H3K27ac and EP300 expression levels and induces apoptosis. JQAD1 suppresses tumors growth in NSG mice xenografted with Kelly cells. CRC and MYCN genes are downregulated in tumors treated with JQAD1. JQAD1 exhibits no significant effect on coactivator CBP at concentrations inducing EP300 degradation.
Targets(IC50)	Apoptosis, Epigenetic Reader Domain, Caspase, Histone Acetyltransferase, PARP, PROTACs
In vitro	JQAD1 (0.5 or 1 μM; 6-96 h) treatment led to early time-dependent induction of sub-G1 peak, indicating that apoptosis of Kelly and NGP cells. JQAD1 (1 μM; 12-36 h) induced apoptosis of Kelly NB cell. JQAD1 (0.5 μM; 24 h) treated cells showed up-regulation of BH3 effectors BIM, BID and PUMA, pro-apoptotic mediator BAX and its inhibitors BCL2 and MCL1. JQAD1 (0.5 and 1 μM; 24 h) destroy expression of MYCN. JQAD1 (0.5 μM; 24 h) lead to H3K27ac deletion on chromatin. JQAD1 (1.2 nM-20 μM; 5 days) has extensive CRBN-dependent anti-tumor activity across cancer cell lines. JQAD1 induced degradation of EP300 in a time-dependent manner, at the earliest 16 hours [1].
In vivo	JQAD1 (40 mg/kg; i.p.; once daily for 21 days) inhibits tumor growth in NSG mice transplanted with Kelly NB cells [1].

## Solubility Information

Solubility	DMSO: 90 mg/mL (96.47 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	1.0719 mL	5.3593 mL	10.7187 mL
5 mM	0.2144 mL	1.0719 mL	2.1437 mL
10 mM	0.1072 mL	0.5359 mL	1.0719 mL
50 mM	0.0214 mL	0.1072 mL	0.2144 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Durbin et al (2021) EP300 selectively controls the enhancer landscape of MYCN-amplified neuroblastoma. Cancer Discov.

Zhang D, Ma B, Liu D, et al. Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy. EBioMedicine. 2024, 105.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481